Compare Sana Biotechnology Inc (SANA) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs United Airlines Holdings Inc — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while United Airlines Holdings Inc trades at $125.25 (market cap $41.00B). The key difference: United Airlines Holdings Inc is far larger — about 36.3× Sana Biotechnology Inc's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | UAL | |
|---|---|---|
Market Cap | $1.13B | $41.00B |
Sector | Health | Industrials |
52-Week High | $5.92 | $136.11 |
52-Week Low | $2.68 | $85.21 |
Enterprise Value | $1.05B | $58.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
United Airlines (UAL) trades at $125.37, up 1.3% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 11.83 and robust ROE of 23.25%. Recent earnings have consistently beaten estimates, and revenue is projected to grow to $62.9B in 2026. Analyst sentiment is overwhelmingly positive with a $167.73 consensus price target and no sell ratings.
The outlook for UAL is favorable due to solid earnings momentum and improving debt metrics, though risks include fuel cost volatility and execution of fleet innovation. The stock presents a value opportunity with upside potential, supported by strong institutional buy-in and manageable liabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
